NDA 019357 · Qol Medcl
Ethamolin
Ethanolamine Oleate · Injection
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 7, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 22, 1988
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
18
18 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 10, 2025.
INDICATIONS AND USAGE ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- ETHAMOLIN · ETHANOLAMINE OLEATE 50MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethanolamine Oleate" as an intervention, any sponsor and status, largest first.
- Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate InjectionPivotal-lookingStatus unknown
Sherief Abd-ElsalamAcademic, hospital or other
NCT03388125 · 113 participants · Start Jan 1, 2016 · Primary completion Aug 1, 2017
Drug: Injection Sclerotherapy; N-butyl-2-cyanoacrylate · For: Bleeding Esophageal Varices
Sites: Tanta, Egypt
Federal University of São PauloAcademic, hospital or other
NCT00799851 · 38 participants · Start Nov 2004 · Primary completion May 2007
Drug: cyanoacrylate injection · For: Liver Disease
Sites: São Paulo, Brazil
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT01101412 · 0 participants
Drug: Edetate Calcium Disodium; Ethanol and 1 more · For: Chronic Myeloproliferative Disorders; Infection; Leukemia and 6 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- oesophageal varices haemorrhage5
- portal vein thrombosis3
- product use in unapproved indication3
- off label use2
- abdominal pain1
- abdominal pain upper1
- anaemia1
- arterial haemorrhage1
- ascites1
- cataract1
- disseminated intravascular coagulation1
- dry eye1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 8 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Ethamolin (Ethanolamine Oleate) · HCPCS J1430
2024 spending
$14K
Beneficiaries
16
26 claims
Per beneficiary
$844
2024 ASP limit $484.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,041 |
| 2021 | $39,529 |
| 2022 | $28,798 |
| 2023 | $21,042 |
| 2024 | $13,504 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage.
Kitamoto M, Imamura M, Kamada K, et al. · AJR Am J Roentgenol 2002 · Clinical Trial
- Treatment of achalasia by injection of sclerosant substances: a long-term report.
Moretó M, Ojembarrena E, Barturen A, et al. · Dig Dis Sci 2013 · Clinical Trial
- Diode laser versus sclerotherapy: bloodless approaches in the treatment of oral pyogenic granuloma (randomised controlled clinical trial).
Anwar SK, Edward SN, ELSayed NM · Odontology 2023 · Randomized Controlled Trial
- Effect and safety of ethanolamine oleate in sclerotherapy in patients with difficult-to-resect venous malformations: A multicenter, single-arm study.
Ozaki M, Nomura T, Osuga K, et al. · PLoS One 2025 · Multicenter Study, Clinical Trial
- Endoscopic injection of ethanolamine as a treatment for achalasia: a first report.
Moretó M, Ojembarrena E, Rodríguez ML · Endoscopy 1996 · Clinical Trial
- Endovascular obliteration of bleeding duodenal varices in patients with liver cirrhosis.
Zamora CA, Sugimoto K, Tsurusaki M, et al. · Eur Radiol 2006 · Clinical Trial
Sponsor: Qol Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.